Defective translational control facilitates vesicular stomatitis virus oncolysis

Cancer Cell - Tập 5 - Trang 51-65 - 2004
Siddharth Balachandran1, Glen N. Barber1
1Department of Microbiology and Immunology and Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL 33136 USA

Tài liệu tham khảo

Anand, 2002, Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer, Nat. Genet., 31, 301, 10.1038/ng904 Asano, 1999, Conserved bipartite motifs in yeast eIF5 and eIF2Bepsilon, GTPase-activating and GDP-GTP exchange factors in translation initiation, mediate binding to their common substrate eIF2, EMBO J., 18, 1673, 10.1093/emboj/18.6.1673 Ashe, 2001, A novel eIF2B-dependent mechanism of translational control in yeast as a response to fusel alcohols, EMBO J., 20, 6464, 10.1093/emboj/20.22.6464 Balachandran, 2000, Vesicular stomatitis virus therapy of tumors, IUBMB Life, 50, 135, 10.1080/713803696 Balachandran, 2000, Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection, Immunity, 13, 129, 10.1016/S1074-7613(00)00014-5 Balachandran, 2001, Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis, J. Virol., 75, 3474, 10.1128/JVI.75.7.3474-3479.2001 Barber, 2001, Host defense, viruses and apoptosis, Cell Death Differ., 8, 113, 10.1038/sj.cdd.4400823 Bergmann, 2001, A genetically engineered influenza A virus with ras-dependent oncolytic properties, Cancer Res., 61, 8188 Clemens, 1997, The double-stranded RNA-dependent protein kinase PKR, J. Interferon Cytokine Res., 17, 503, 10.1089/jir.1997.17.503 Dever, 1993, Mammalian eukaryotic initiation factor 2 alpha kinases functionally substitute for GCN2 protein kinase in the GCN4 translational control mechanism of yeast, Proc. Natl. Acad. Sci. USA, 90, 4616, 10.1073/pnas.90.10.4616 Fabian, 1997, Subunit assembly and guanine nucleotide exchange activity of eukaryotic initiation factor-2B expressed in Sf9 cells, J. Biol. Chem., 272, 12359, 10.1074/jbc.272.19.12359 Farassati, 2001, Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1, Nat. Cell Biol., 3, 745, 10.1038/35087061 Fernandez, 2002, Genetically engineered vesicular stomatitis virus in gene therapy, J. Virol., 76, 895, 10.1128/JVI.76.2.895-904.2002 Flowers, 1996, Cloning and characterization of complementary and genomic DNAs encoding the epsilon-subunit of rat translation initiation factor-2B, Biochim. Biophys. Acta, 1307, 318, 10.1016/0167-4781(96)00055-3 Gomez, 2002, Characterization of the minimal catalytic domain within eIF2B, EMBO J., 21, 5292, 10.1093/emboj/cdf515 Hahn, 1999, Creation of human tumour cells with defined genetic elements, Nature, 400, 464, 10.1038/22780 Harding, 2000, Perk is essential for translational regulation and cell survival during the unfolded protein response, Mol. Cell, 5, 897, 10.1016/S1097-2765(00)80330-5 Hershey, 1991, Translational control in mammalian cells, Annu. Rev. Biochem., 60, 717, 10.1146/annurev.bi.60.070191.003441 Hinnebusch, 1994, The eIF-2 alpha kinases, Semin. Cell Biol., 5, 417, 10.1006/scel.1994.1049 Kim, 2000, Human breast cancer cells contain elevated levels and activity of the protein kinase, PKR, Oncogene, 19, 3086, 10.1038/sj.onc.1203632 Kimball, 1999, Eukaryotic initiation factor eIF2, Int. J. Biochem. Cell Biol., 31, 25, 10.1016/S1357-2725(98)00128-9 Kimball, 1998, Regulation of guanine nucleotide exchange through phosphorylation of eukaryotic initiation factor eIF2alpha. Role of the alpha- and delta- subunits of eiF2b, J. Biol. Chem., 273, 12841, 10.1074/jbc.273.21.12841 Lawson, 1995, Recombinant vesicular stomatitis viruses from DNA, Proc. Natl. Acad. Sci. USA, 92, 4477, 10.1073/pnas.92.10.4477 Lee, 1999, Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associated lymphomas, Cancer Res., 59, 5514 Obuchi, 2003, Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity, J. Virol., 77, 8843, 10.1128/JVI.77.16.8843-8856.2003 Pavitt, 1997, Homologous segments in three subunits of the guanine nucleotide exchange factor eIF2B mediate translational regulation by phosphorylation of eIF2, Mol. Cell. Biol., 17, 1298, 10.1128/MCB.17.3.1298 Pavitt, 1998, eIF2 independently binds two distinct eIF2B subcomplexes that catalyze and regulate guanine-nucleotide exchange, Genes Dev., 12, 514, 10.1101/gad.12.4.514 Proud, 2001, Regulation of eukaryotic initiation factor eIF2B, Prog. Mol. Subcell. Biol., 26, 95, 10.1007/978-3-642-56688-2_4 Ron, 2002, Translational control in the endoplasmic reticulum stress response, J. Clin. Invest., 110, 1383, 10.1172/JCI0216784 Savinova, 1999, Abnormal levels and minimal activity of the dsRNA-activated protein kinase, PKR, in breast carcinoma cells, Int. J. Biochem. Cell Biol., 31, 175, 10.1016/S1357-2725(98)00140-X Sonenberg, 1993, Translation factors as effectors of cell growth and tumorigenesis, Curr. Opin. Cell Biol., 5, 955, 10.1016/0955-0674(93)90076-3 Stark, 1998, How cells respond to interferons, Annu. Rev. Biochem., 67, 227, 10.1146/annurev.biochem.67.1.227 Stojdl, 2000, Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus, Nat. Med., 6, 821, 10.1038/77558 Strong, 1998, The molecular basis of viral oncolysis, EMBO J., 17, 3351, 10.1093/emboj/17.12.3351 Vazquez de Aldana, 1994, Mutations in the GCD7 subunit of yeast guanine nucleotide exchange factor eIF-2B overcome the inhibitory effects of phosphorylated eIF-2 on translation initiation, Mol. Cell. Biol., 14, 3208, 10.1128/MCB.14.5.3208 Vojtechova, 2003, Initiation factor eIF2B not p70 S6 kinase is involved in the activation of the PI-3K signalling pathway induced by the v-src oncogene, FEBS Lett., 543, 81, 10.1016/S0014-5793(03)00415-0 Williams, 2001, Characterization of the initiation factor eIF2B and its regulation in Drosophila melanogaster, J. Biol. Chem., 276, 3733, 10.1074/jbc.M008041200 Zimmer, 2000, Translational control of malignancy, Anticancer Res., 20, 1343